Latest Generate:Biomedicines News & Updates

See the latest news and media coverage for Generate. We track all announcements, press releases, and industry mentions in real time, all in one place.

Generate:Biomedicines (Generate)

Generative biology therapeutics company

generatebiomedicines.com

Headquarters: Somerville, United States
Company type: Private company
Number of employees: 330–500
Industry: Pharmaceuticals

Last updated October 22

Latest news about Generate:Biomedicines (Generate)

In short: Generate completed a $400M IPO, advanced GB-0895 Phase 3 trials, and struck a $1.2B Zealand Pharma deal.

Company announcements

October 13 Generate

Generate Biomedicines partners with Zealand Pharma for AI drug development

The collaboration leverages generative AI to create protein therapeutics for metabolic diseases. Generate receives up to $1.2B in milestones and royalties.

October 1 Generate

Generate Biomedicines doses first patient for GB-5267 CAR T trial

The therapy targets ovarian cancer. It uses an AI-enabled generative biology platform to engineer functional traits.

August 10 Generate

Generate:Biomedicines reports Q2 2026 financial results

Company advances GB-0895 Phase 3 trials, enrolls first cohort for GB-4362, and holds $457.4M cash.

August 6 Generate

Generate:Biomedicines announced its second-quarter 2026 results

It highlighted progress across its platform, pipeline, and strategic collaborations, connecting computational design with large-scale experimentation and development.

Media coverage

October 22 Longevity Technology

Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal

Zealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly ...

October 15 AInvest

GENB Slumps 18% Despite a Strong Buy Rating

Generate Biomedicines (GENB.O) fell 18.41% after a risk disclosure highlighted dependency on partner acceptance for future ...

October 13 BioWorld

Zealand in $1.2B+ protein drug deal with AI specialist Generate

Zealand Pharma A/S is moving further out of its comfort zone in peptides to venture into developing biologics for metabolic diseases in a collaboration with...

October 1 BioSpace

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer - BioSpace

BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roswell Park Comprehensive Cancer Center (“Roswell Park”) and Generate Biomedicines, Inc.

Never miss news about Generate

Track Generate and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Generate competitors & trending companies

Browse news for competitors to Generate and other trending companies.